Skip to main content
. 2003 Jul 7;198(1):91–98. doi: 10.1084/jem.20030615

Figure 3.

Figure 3.

(A) Kaplan-Meier tumor-free survival estimates for Btk-deficient (dotted line), SLP-65−/− (thin line), and Btk-SLP-65−/− mice (bold line). Tumor-free survival in Btk-SLP-65−/− mice was significantly reduced (P < 0.0001 by log-rank) compared with SLP-65−/− mice. (B) Kaplan-Meier tumor-free survival estimates for SLP-65−/− (thin line) and BtkActSLP-65−/− mice (dotted line). Tumor-free survival in BtkActSLP-65−/− mice was significantly enhanced (P = 0.04 by log-rank) compared with SLP-65−/− mice.